Pharmafile Logo
Pharmafocus logo
Advanced Search

Teva

Showing 15 posts of 235 posts found.

Teva image

Teva forges ahead with Mylan pursuit

May 6, 2015
Sales and Marketing Mylan, Perrigo, Teva, generics

Teva has reinforced its commitment to buy Mylan despite previous rejection and only days after Mylan upped its own bid …

News
Perrigo image

Perrigo bats away raised Mylan bid

April 30, 2015
Sales and Marketing Mylan, Perrigo, Teva, Vigodman, merger

Perrigo has rejected an updated $34.1 billion takeover bid from Mylan, whilst Teva has also written an open letter in …

News
abilify_bms_otsuka

FDA waves through generic BMS antipsychotic

April 30, 2015
Manufacturing and Production, Sales and Marketing Alembic, BMS, FDA, Hetero and Torrent Pharmaceuticals, Teva

The FDA has approved four generic versions of Bristol-Myers Squibb’s top selling Abilify, an atypical antipsychotic drug approved to treat …

News
teva_copy

M&A drama continues as Mylan rejects Teva

April 28, 2015
Sales and Marketing M&A, MA, Mylan, Perrigo, Teva, bids, generics, takeovers

Mylan has firmly rejected Teva’s acquisition bid, even though its own bid for Irish firm Perrigo has also been turned …

News
Teva image

Teva faces $512m fine in generic Provigil row

April 22, 2015
Sales and Marketing Cephalon, Mylan, Teva, generic, modafinil, provigil

Teva has agreed to a record $512 million settlement in a ‘pay-to-delay’ row over generic versions of its drug Provigil. …

News
Teva image

Teva moves to buy Mylan

April 21, 2015
Research and Development, Sales and Marketing India, Mylan, Perrigo, Teva, US, Vigodman, generics, israel, merger

Israeli generics drug giant Teva has made an offer to buy its US rival Mylan for around $40.1 billion. The …

News
Copaxone image

FDA approves generic Copaxone for multiple sclerosis

April 17, 2015
Sales and Marketing FDA, Sandoz, Teva, glatiramer acetate injection, glatopa

The FDA has signed-off on the first generic version of Copaxone to treat people with relapsing forms of multiple sclerosis …

News
Teva image

Teva bolsters neurology unit through Auspex deal

March 31, 2015
Sales and Marketing CNS, SD-809, Teva, Tourette syndrome, auspex, deutetrabenazine, neurology

Teva is significantly enhancing its neurology business by acquiring US biopharma firm Auspex in a deal worth $3.5 billion. Teva …

News
timothy_wright_teva

Teva hires new business development head

March 25, 2015
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Teva, timothy wright

Teva Pharmaceutical Industries has confirmed the appointment of Timothy Wright to its executive leadership team to head up business development, …

Appointment
Teva image

Teva and Ignyta shake hands in oncology deal

March 19, 2015
Research and Development, Sales and Marketing CEP-32496, CEP-40125, Levact, RXDX-105, Teva, ignyta, oncology

Ignyta has acquired four oncology R&D assets from Israeli pharma generics giant Teva in a deal worth around $42 million. …

News
Teva image

Teva to sell US manufacturing plant

March 4, 2015
Manufacturing and Production, Sales and Marketing G&W Laboratories, Pennsylvania, Teva

Teva Pharmaceutical has announced that it has signed an agreement to sell a US manufacturing facility to G&W Laboratories. The …

News
Teva image

US Supreme Court backs Teva in Copaxone patent case

January 28, 2015
Sales and Marketing Copaxone, Momenta Pharmaceuticals, Mylan, Natco Pharma, Teva

Teva has won a US Supreme Court judgement allowing it to continue marketing its multiple sclerosis drug Copaxone without challenge …

News
Nexium image

Teva’s Nexium copycat approved in US

January 27, 2015
Manufacturing and Production, Sales and Marketing AstraZeneca, Teva, esomeprazole, gerd, heart, nsaids

Teva has won approval for its copycat form of AstraZeneca’s big-selling heatburn drug Nexium, making it the first generic version …

News
Yitzhak Peterburg image

New Teva chairman announced

November 28, 2014
Manufacturing and Production, Sales and Marketing Phillip Frost, Teva, Yitzhak Peterburg, barer, generics, israel

Teva Pharmaceutical Industries has confirmed that Professor Yitzhak Peterburg is to serve as its new chairman from January. Peterburg who …

News
Teva image

Teva to ditch R&D in cancer and women’s health

October 6, 2014
Manufacturing and Production, Research and Development, Sales and Marketing Copaxone, FDA, MS, R&D, Teva, cuts, generics

Teva will stop research into oncology and women’s health in order to cut costs and focus more on generics and …

News
The Gateway to Local Adoption Series

Latest content

Siemens Healthineers opens 10m euro R&D centre for laboratory equipment in Ireland

February 19, 2026

Everdrone announces new board of directors to drive expansion

February 19, 2026

Regeneron announces presentations of new data on Eylea HD for retinal disease

February 18, 2026

Indegene completes acquisition of Cake Health

February 18, 2026

Gedeon Richter UK acquires rights to schizophrenia treatment Reagila from Recordati Pharmaceuticals

February 17, 2026